238 related articles for article (PubMed ID: 24623800)
1. Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors.
Wang J; Li W
J Pharmacol Exp Ther; 2014 May; 349(2):319-29. PubMed ID: 24623800
[TBL] [Abstract][Full Text] [Related]
2. Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2.
Cossu F; Mastrangelo E; Milani M; Sorrentino G; Lecis D; Delia D; Manzoni L; Seneci P; Scolastico C; Bolognesi M
Biochem Biophys Res Commun; 2009 Jan; 378(2):162-7. PubMed ID: 18992220
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors.
Wang Q; Arnst KE; Xue Y; Lei ZN; Ma D; Chen ZS; Miller DD; Li W
Eur J Med Chem; 2018 Apr; 149():211-224. PubMed ID: 29501942
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.
Zobel K; Wang L; Varfolomeev E; Franklin MC; Elliott LO; Wallweber HJ; Okawa DC; Flygare JA; Vucic D; Fairbrother WJ; Deshayes K
ACS Chem Biol; 2006 Sep; 1(8):525-33. PubMed ID: 17168540
[TBL] [Abstract][Full Text] [Related]
5. Design of small-molecule Smac mimetics as IAP antagonists.
Wang S
Curr Top Microbiol Immunol; 2011; 348():89-113. PubMed ID: 21072626
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design and molecular profiling of Smac-mimetics selective for cellular IAPs.
Corti A; Milani M; Lecis D; Seneci P; de Rosa M; Mastrangelo E; Cossu F
FEBS J; 2018 Sep; 285(17):3286-3298. PubMed ID: 30055105
[TBL] [Abstract][Full Text] [Related]
7. Design of small-molecule peptidic and nonpeptidic Smac mimetics.
Sun H; Nikolovska-Coleska Z; Yang CY; Qian D; Lu J; Qiu S; Bai L; Peng Y; Cai Q; Wang S
Acc Chem Res; 2008 Oct; 41(10):1264-77. PubMed ID: 18937395
[TBL] [Abstract][Full Text] [Related]
8. Bivalent SMAC Mimetics for Treating Cancer by Antagonizing Inhibitor of Apoptosis Proteins.
Zhu H; Li Y; Liu Y; Han B
ChemMedChem; 2019 Dec; 14(23):1951-1962. PubMed ID: 31692274
[TBL] [Abstract][Full Text] [Related]
9. Modulation of Respiration and Mitochondrial Dynamics by SMAC-Mimetics for Combination Therapy in Chemoresistant Cancer.
Hagenbuchner J; Oberacher H; Arnhard K; Kiechl-Kohlendorfer U; Ausserlechner MJ
Theranostics; 2019; 9(17):4909-4922. PubMed ID: 31410190
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transport.
Talbott RL; Borzilleri RM; Chaudhry C; Fargnoli J; Shen H; Fairchild C; Barnhart B; Ortega M; McDonagh TE; Vuppugalla R; Vite GD; Hunt JT; Gottardis M; Naglich JG
Exp Cell Res; 2015 Nov; 338(2):251-60. PubMed ID: 26302264
[TBL] [Abstract][Full Text] [Related]
11. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP.
Vucic D; Franklin MC; Wallweber HJ; Das K; Eckelman BP; Shin H; Elliott LO; Kadkhodayan S; Deshayes K; Salvesen GS; Fairbrother WJ
Biochem J; 2005 Jan; 385(Pt 1):11-20. PubMed ID: 15485396
[TBL] [Abstract][Full Text] [Related]
12. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D
Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP.
Sun H; Nikolovska-Coleska Z; Lu J; Meagher JL; Yang CY; Qiu S; Tomita Y; Ueda Y; Jiang S; Krajewski K; Roller PP; Stuckey JA; Wang S
J Am Chem Soc; 2007 Dec; 129(49):15279-94. PubMed ID: 17999504
[TBL] [Abstract][Full Text] [Related]
14. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
Ng CP; Bonavida B
Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis and Structure-Activity Relationship Studies of Novel Survivin Inhibitors with Potent Anti-Proliferative Properties.
Xiao M; Wang J; Lin Z; Lu Y; Li Z; White SW; Miller DD; Li W
PLoS One; 2015; 10(6):e0129807. PubMed ID: 26070194
[TBL] [Abstract][Full Text] [Related]
16. Smac modulates chemosensitivity in head and neck cancer cells through the mitochondrial apoptotic pathway.
Sun Q; Zheng X; Zhang L; Yu J
Clin Cancer Res; 2011 Apr; 17(8):2361-72. PubMed ID: 21242120
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582).
Hennessy EJ; Adam A; Aquila BM; Castriotta LM; Cook D; Hattersley M; Hird AW; Huntington C; Kamhi VM; Laing NM; Li D; MacIntyre T; Omer CA; Oza V; Patterson T; Repik G; Rooney MT; Saeh JC; Sha L; Vasbinder MM; Wang H; Whitston D
J Med Chem; 2013 Dec; 56(24):9897-919. PubMed ID: 24320998
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.
Welsh K; Milutinovic S; Ardecky RJ; Gonzalez-Lopez M; Ganji SR; Teriete P; Finlay D; Riedl S; Matsuzawa S; Pinilla C; Houghten R; Vuori K; Reed JC; Cosford ND
PLoS One; 2016; 11(9):e0161952. PubMed ID: 27617834
[TBL] [Abstract][Full Text] [Related]
19. Structural insight into inhibitor of apoptosis proteins recognition by a potent divalent smac-mimetic.
Cossu F; Milani M; Vachette P; Malvezzi F; Grassi S; Lecis D; Delia D; Drago C; Seneci P; Bolognesi M; Mastrangelo E
PLoS One; 2012; 7(11):e49527. PubMed ID: 23166698
[TBL] [Abstract][Full Text] [Related]
20. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
